Sean McEvoy

Vice President, Biopharma Partnerships

Sean McEvoy, VP Biopharma Partnerships

About Sean McEvoy

Sean McEvoy is a results-oriented professional with over 20 years of experience as a business development and commercial team leader in laboratory diagnostics and clinical health sciences. Throughout his career, he has been dedicated to creating organizations that provide innovative diagnostic solutions to support therapeutic development and improve patient outcomes. Sean has a diverse range of skills and experience including: corporate and organizational development, investor relations and funding, strategic alliance management, global partnerships and joint ventures, contracting and service agreements, strategic market assessment, reimbursement strategy, regulatory, and compliance.

In his current role at Amprion, Sean is responsible for leading the development and implementation of a strategic plan for global biopharma partnerships to support clinical research and therapeutic development for neurodegenerative disorders. Before joining Amprion, he established a global business development team at Blueprint Genetics and oversaw the expansion of biopharma programs for rare-inherited disorders. Sean also held various leadership positions at Claritas Genomics, GeneDx, and Athena Diagnostics.

Sean completed his undergraduate education in biological sciences (neuroscience) and philosophy (ethics) at USC in Los Angeles, CA, and continued with his graduate education in neuroscience and pharmacology at OHSU in Portland, OR. Sean has several years of experience in basic science research having been employed as a research assistant at HEDCO Neuroscience (USC) and the Center for Research on Occupational and Environmental Toxicology which was renamed Oregon Institute of Occupational Health Science in 2013 (OHSU). 

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.

Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.